Ani Pharmaceuticals (ANIP) Total Liabilities (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Total Liabilities data on file, last reported at $859.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 1.26% year-over-year to $859.7 million; the trailing twelve-month figure through Mar 2026 stood at $859.7 million (up 1.26% YoY), and the FY2025 full-year result was $899.7 million, up 5.11% from the prior year.
• Total Liabilities slipped to $859.7 million in Q1 2026, from $899.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $902.3 million in Q3 2025 to a low of $398.8 million in Q1 2022.
• A 5-year average of $608.9 million and a median of $440.1 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 100.25% in 2025 and increased 1.26% in 2026, its largest moves.
• Tracing ANIP's Total Liabilities over 5 years: stood at $421.5 million in 2022, then grew by 6.0% to $446.8 million in 2023, then jumped by 91.56% to $855.9 million in 2024, then increased by 5.11% to $899.7 million in 2025, then dropped by 4.44% to $859.7 million in 2026.
• Business Quant data shows ANIP's Total Liabilities at $859.7 million in Q1 2026, $899.7 million in Q4 2025, and $902.3 million in Q3 2025.